TBPH Q1 2018 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+169.5% YoY

Gross Profit

$7M90.1% margin

Operating Income

-$65M-781.1% margin

Net Income

-$65M-782.4% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

+84.3%

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

$47M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$480M

Total Liabilities

$417M

Stockholders' Equity

$63M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$3M	+169.5%
Gross Profit	$7M	$3M	+197.1%
Operating Income	-$65M	-$59M	-10.4%
Net Income	-$65M	-$65M	+0.4%

Revenue Segments

Collaborative Arrangements

$5M56%

Product

$4M44%